Oncology research continues to unveil promising therapeutic candidates and mechanisms. Panobinostat enhances adagrasib-mediated killing of non-small cell lung cancer cells by inducing autophagy, indicating a potent combinatorial strategy. Longitudinal data on 4D Molecular Therapeutics’ gene therapy demonstrate sustained efficacy in diabetic macular edema. Phase 3 trial results of pembrolizumab plus axitinib show significant survival improvements in advanced kidney cancer. Additionally, clinical studies reveal novel biomarkers and target candidates for muscle-invasive bladder cancer and glioblastoma, broadening options for personalized cancer care.